Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Non-medullary thyroid carcinoma.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Hormones | 1 | Non-medullary thyroid carcinoma |
Biomarker and diagnostic research for thyroid cancer, nonmedullary, 3 has been reported in the published literature.
No clinical trials have been registered for thyroid cancer, nonmedullary, 3.
264 publications have been identified in PubMed for thyroid cancer, nonmedullary, 3. Kisho has analyzed 83 by research type. Research spans Basic Science / Preclinical (28%), Epidemiology / Natural History (24%), and Review / Meta-Analysis (14%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 23 | 28% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 8:53 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Disease patterns and progression |
20 |
24% |
Research summaries | 12 | 14% |
Testing and diagnosis research | 11 | 13% |
Clinical study results | 9 | 11% |
Patient case studies | 4 | 5% |
New treatment approaches | 4 | 5% |
Yılmaz S (2026). [PMID: 41765079](https://pubmed.ncbi.nlm.nih.gov/41765079/). *J Vasc Interv Radiol*. [Clinical Trial Publication]
Gui S (2026). [PMID: 41565206](https://pubmed.ncbi.nlm.nih.gov/41565206/). *Mol Cell Proteomics*. [Basic Science / Preclinical]
Patrizio A (2026). [PMID: 41376649](https://pubmed.ncbi.nlm.nih.gov/41376649/). *J Endocr Soc*. [Clinical Trial Publication]
Francis DO (2026). [PMID: 41733915](https://pubmed.ncbi.nlm.nih.gov/41733915/). *JAMA Netw Open*. [Basic Science / Preclinical]
Zhao Z (2025). [PMID: 40726357](https://pubmed.ncbi.nlm.nih.gov/40726357/). *Int J Hyperthermia*. [Clinical Trial Publication]
Rocco D (2025). [PMID: 40869275](https://pubmed.ncbi.nlm.nih.gov/40869275/). *Int J Mol Sci*. [Case Report / Case Series]
Wei K (2025). [PMID: 40040415](https://pubmed.ncbi.nlm.nih.gov/40040415/). *Head Neck*. [Diagnostic / Biomarker]
Deziel NC (2025). [PMID: 40209106](https://pubmed.ncbi.nlm.nih.gov/40209106/). *Environ Health Perspect*. [Epidemiology / Natural History]
Ward KR (2025). [PMID: 40590273](https://pubmed.ncbi.nlm.nih.gov/40590273/). *Am J Clin Oncol*. [Epidemiology / Natural History]
Trivedi V (2025). [PMID: 40440572](https://pubmed.ncbi.nlm.nih.gov/40440572/). *JCO Glob Oncol*. [Basic Science / Preclinical]
AI-curated news mentioning thyroid cancer, nonmedullary, 3
Updated Sep 10, 2026
Sapanisertib shows promise for treating rare mTOR-driven disorders, with potential applications in various cancers including bladder and ovarian cancer. Successful late-stage clinical development could unlock orphan-drug incentives and enhance adoption in specialized treatment centers.
A recent study indicates that incidentally detected papillary thyroid carcinoma does not negatively affect pregnancy outcomes during fertility treatment. This finding may influence clinical practices regarding the management of thyroid cancer in women seeking fertility assistance.
A nationwide database study investigates the prevalence and outcomes of metastases to the thyroid gland, providing valuable insights into this rare occurrence. The findings may inform clinical practices and patient management strategies.
The updated Dutch 2026 guidelines for pediatric differentiated thyroid carcinoma align with European standards, enhancing treatment protocols. This update reflects ongoing efforts to standardize care across regions for this rare cancer.